Sensitive and Rapid HPLC Quantification of Tenofovir from Hyaluronic Acid-Based Nanomedicine
- 569 Downloads
The purpose of this study was to develop and validate a rapid, sensitive, and specific reversed-phase high-performance liquid chromatography method for the quantitative determination of native tenofovir (TNF) for various applications. Different analytical performance parameters such as linearity, precision, accuracy, limit of quantification (LOQ), limit of detection (LOD), and robustness were determined according to International Conference on Harmonization (ICH) guidelines. A Bridge™ C18 column (150 × 4.6 mm, 5 μm) was used as stationary phase. The retention time of TNF was 1.54 ± 0.03 min (n = 6). The assay was linear over the concentration range of 0.1–10 μg/mL. The proposed method was sensitive with LOD and LOQ values equal to 50 and 100 ng/mL, respectively. The method was accurate with percent mean recovery from 95.41% to 102.90% and precise as percent RSD (relative standard deviation) values for intra-day, and inter-day precision were less than 2%. This method was utilized for the estimation of molar absorptivity of TNF at 259 nm (ε 259 = 12,518 L/mol/cm), calculated from linear regression analysis. The method was applied for determination of percentage of encapsulation efficiency ( 22.93 ± 0.04%), drug loading (12.25 ± 1.03%), in vitro drug release profile in the presence of enzyme (43% release in the first 3 h) and purification analysis of hyaluronic acid-based nanomedicine.
KEY WORDShigh-performance liquid chromatography hyaluronic acid molar absorptivity nanomedicine tenofovir
The project described was supported by Grant Number R01AI087304 from the National Institute of Allergy And Infectious Diseases. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy And Infectious Diseases or the National Institutes of Health. We gratefully acknowledge Mr. Jack Liu (Zhenjiang Dong Yuan Biotech Co., Ltd., Jiangsu, China) for providing samples of hyaluronic acid.
- 20.Raju NA. Simultaneous estimation of tenofovir disproxil fumerate, emtricitabine & efavirenz in tablet dosage forms by isocratic-RP-HPLC. J Pharm Res. 2009;2(6):1103–6.Google Scholar
- 27.Swyer GI. The hyaluronidase content of semen. Biochem J. 1947;41(3):409–13.Google Scholar
- 29.Khan A, Khan MI, Iqbal Z, Shah Y, Ahmad L, Watson DG. An optimized and validated RP-HPLC/UV detection method for simultaneous determination of all-trans-retinol (vitamin A) and alpha-tocopherol (vitamin E) in human serum: comparison of different particulate reversed-phase HPLC columns. J Chromatogr B Analyt Technol Biomed Life Sci. 2010;878(25):2339–47.PubMedCrossRefGoogle Scholar
- 32.ICH Guideline. Q2 (R1). Validation of analytical procedures: text and methodology. Geneva Switzerland: ICH Secretariat; 2005.Google Scholar
- 34.Hu Z, Xia X, Tang L (inventors). Process for synthesizing oil and surfactant-free hyaluronic acid nanoparticles and microparticles. United States patent 7,601,704 B2. 2009 October 13.Google Scholar
- 35.Hackley V, Ferraris C. The use of nomenclature in dispersion science and technology, NIST Recommended Practice Guide. NIST SP. 2001; 960-3; 72; SPGoogle Scholar
- 39.Patel S, Baghel US, Rajesh P, Prabhakar D, Engla G, Nagar PN. Spectrophotometric method development and validation for simultaneous estimation of tenofovir disoproxil fumarate and emtricitabine in bulk drug and tablet dosage form. Int J Pharm Clin Res. 2009;1:28–30.Google Scholar
- 40.O'Neil MJ, Smith A, Heckelman PE. The Merck index. 13th ed. New Jersey: Merck research laboratories; 2001.Google Scholar